Vertex Pharmaceuticals Inc (VRTX) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.

Total Assets Chart for Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc (VRTX) total assets for FY2025 were USD 26.1B, a 16.0% change from FY2024. Vertex Pharmaceuticals Inc's total assets grew from USD 9.2M in 1990 to USD 26.1B in 2025 (284060.9% over 35 years). Total assets compound annual growth rate: 5-year CAGR of 17.3%, 10-year CAGR of 26.5%, 20-year CAGR of 21.3%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$122.68B
Implied Share Price
$484.03
Enterprise Value
$117.01B
Revenue (TTM)
$12.59B
EBITDA
$5.10B
Profit Margin
35.00%
Trailing P/E
28.26
Forward P/E
24.88
Price/Book (MRQ)
5.99
Price/Sales (TTM)
9.75
EV/EBITDA
22.88
EV/Revenue
9.17
Dividend Yield
—
Book Value
$79.92
Free Cash Flow (FY2025)
$3.19B
Free Cash Flow Yield
2.60%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.